DR. SHAILLY TOMAR (Orcid ID : 0000-0002-1730-003X)

Received Date : 26-Aug-2019

Revised Date : 23-Sep-2019

Accepted Date : 02-Oct-2019

Article type : Research Articles

# Inhibition of Chikungunya virus by an Adenosine Analog targeting the SAM-dependent nsP1 methyltransferase

Rajat Mudgal<sup>1</sup>, Supreeti Mahajan<sup>a</sup>, Shailly Tomar<sup>a,@,©</sup>

# ABSTRACT

Alphaviruses, including Chikungunya (CHIKV) and Venezuelan equine encephalitis virus (VEEV), are among the leading causes of recurrent epidemics all over the world. Alphaviral nonstructural protein 1 (nsP1) orchestrates the capping of nascent viral RNA via its S-adenosyl methionine-dependent N-7-methyltransferase (MTase) and guanylyltransferase activities. Here,

<sup>Θ</sup> Corresponding Author

<sup>&</sup>lt;sup>1</sup> Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee 247667, Uttarakhand, India

<sup>&</sup>lt;sup>®</sup> Address Correspondence to Shailly Tomar, <u>shailfbt@iitr.ac.in</u>

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the <u>Version of Record</u>. Please cite this article as <u>doi: 10.1002/1873-3468.13642</u>

we developed and validated a novel capillary electrophoresis (CE)-based assay for measuring the MTase activity of purified VEEV and CHIKV nsP1. We employed the assay to assess the MTase inhibition efficiency of a few adenosine analogs and identified 5-iodotubercidin (5-IT) as an inhibitor of nsP1. The antiviral potency of 5-IT was evaluated *in vitro* using a combination of cell-based assays, which suggest that 5-IT is efficacious against CHIKV in cell culture (EC<sub>50</sub>: 0. 409  $\mu$ M).

**Keywords:** nsP1, CE-based MTase assay, alphavirus inhibitor, adenosine analog, Chikungunya virus

# **ABBREVIATIONS**

5-IT: 5-iodotubercidin **BGE**: background electrolyte **CE**: capillary electrophoresis **CHIKV**: Chikungunya virus **DAPI**: 4',6-diamidino-2-phenylindole EEEV: Eastern equine encephalitis virus ELISA: enzyme-linked immunosorbent assay **GIDP**: guanosine 5'- $[\beta, \gamma$ -imido]triphosphate **GT**: guanylation GTase: guanylyltransferase MALDI-TOF: matrix-assisted laser desorption-time of flight spectrometer MTase: methyltransferase **nsP1**: non-structural protein 1 NW: New World **OW**: Old World **PFU**: plaque-forming units **PVA**: poly-vinyl alcohol **qRT-PCR**: quantitative reverse transcription polymerase chain reaction SAH: S-adenosyl homocysteine SAM: S-adenosyl methionine

#### INTRODUCTION

Emergence and re-emergence of mosquito-borne viral pathogens including alphaviruses such as Chikungunya (CHIKV) and Venezuelan equine encephalitis virus (VEEV) represent a significant health threat to the human population worldwide. Alphaviruses are classified based on their geographical distribution into New World (NW) and Old World (OW) alphaviruses (1). OW alphaviruses are generally arthrogenic and include CHIKV and Sindbis virus while NW alphaviruses such as VEEV, Eastern equine encephalitis virus (EEEV) and Western equine encephalitis virus are characterized by an encephalitogenic phenotype (1, 2). Alphaviruses replicate to very high titers in cell lines of mosquito and vertebrate origins, possess capability of storage in lyophilized form and their potential of spread in aerosol form makes them potential bioweapons (3). Thus, these viruses are recognized as category B priority pathogens by the U.S. government. VEEV has caused major epidemics in several parts of the world involving a large number of equids and humans (4). CHIKV has been documented to cause disease since 1953 but its explosive outbreak in 2005 in La Rèunion Island involved an overwhelming number of 300,000 reported cases (5). Since 2005, it has caused recurrent outbreaks in Asia and other parts of the world. The lack of effective and safe antiviral agents against alphaviruses including CHIKV and VEEV makes the pursuit of compounds with antiviral activity against these viruses highly imperative.

In alphaviruses, individual non-structural proteins (nsPs) are produced post-translationally after processing of a non-structural polyprotein and they play an indispensable role in the alphaviral life cycle (2). Capping of the viral genome is a vital step in the alphaviral life cycle as this cap structure plays numerous biological roles including the protection of mRNAs from cellular exonucleases and efficient recognition of the RNA by eukaryotic translation initiation factor 4E (eIF4E) for the initiation of translation (6). Additionally, this cap structure also prevents recognition by members of the host innate immune pathways such as MDA5 and/or RIG-I (7). Alphaviruses use a completely distinct molecular mechanism of capping of viral mRNA from the host cell. Cellular capping enzymes typically methylate GTP only after its transfer to the 5' end of the RNA. In contrast, the alphaviral capping enzyme, non-structural protein 1 (nsP1) caps viral RNAs in two major steps: it first methylates GTP by transferring the methyl group from S-

adenosyl methionine (SAM), which acts as the methyl donor, to GTP and the methylated m<sup>7</sup>GMP moiety gets covalently attached to the nsP1 enzyme transiently during a guanylation (GT) step (8). S-adenosyl homocysteine (SAH) is generated as a co-product of this methyltransferase (MTase) step of capping reaction. The amino-terminal of nsP2, another replication protein of alphavirus, harbours the RNA triphosphatase activity (9). It contributes to the capping reaction of alphaviruses by cleaving the  $\gamma$ , $\beta$ -triphosphate bond specifically at the 5' end of the nascent RNA prior to the transfer of m<sup>7</sup>GMP to the nascent viral RNA by nsP1 in the guanylyltransferase (GTase) step. Mutational analyses of the protein and reverse genetics studies involving live virus showed that the abrogation of alphaviral nsP1 activity is detrimental to the viral growth proving that nsP1 capping activity is an essential step during viral replication (10).

Viruses within the alphavirus superfamily have been shown to replicate in membrane invaginations (spherules) in the host cell. nsP1 is also a vital component of the replication complex as it anchors the ensemble of nsPs and other replication factors on the membrane primarily through an amphipathic helix and secondarily through palmitoylation sites on the protein residues (11–13). The three-dimensional structure of alphavirus nsP1 from any member of the alphavirus genus remains elusive. In the absence of the 3D structure of nsP1, the development of enzymatic assays for the screening or development of potent inhibitors targeting replication protein nsP1 is required. It will provide a platform for the identification and characterization of inhibitors of this viral enzyme for treating diseases caused by alphaviral infection. Lately, there has been a surge in the development of novel assays for nsP1 enzymatic activity to accentuate the pursuit of novel antiviral compounds. Previous efforts for the development of the assays for the biochemical characterization and inhibition assays against nsP1 were focussed on the GT step of the nsP1 enzymatic reaction (14-16). Gel-based approach for inhibition study used a fluorescently labelled GTP (GTP-ATTO) for detection or western blot/ELISA uses anti-m<sup>3</sup>G/m<sup>7</sup>G-cap monoclonal antibodies for quantification of nsP1 enzymatic activity (14-16). These immuno-based assays target GT activity inhibition, utilize expensive antibodies, are labor-intensive and susceptible to the identification of false-positives/false-negatives. A fluorescence polarisation-based assay has also been developed for nsP1 which is used for screening of small molecules against CHIKV nsP1. This assay is based on monitoring the displacement of fluorescently labelled GTP analog by an inhibitory molecule (17). The screening potential of this FP-based assay is restricted to the compounds competing for the GTP-binding site on the enzyme.

Nucleosides/nucleoside analogs represent a major class of antiviral drugs (18). Nucleoside analogs have been shown to display antiviral activity against several medically important viruses including HIV, hepatitis B virus and herpesvirus (19, 20). Sinefungin and other SAM/nucleoside analogs have been shown to inhibit viral MTase activity and consequently abrogates viral replication *in vitro* in the members of flavivirus family including the Zika virus, West Nile virus and Dengue virus (21–24). Regarding alphaviruses, broad-spectrum antiviral agents ribavirin and favipiravir, have been shown to have *in vitro* anti-VEEV and anti-CHIKV activity respectively (25, 26). Additionally, a cytosine analog, D-(-)-carbodine, showed moderate *in vivo* efficacy against VEEV (27). More recently, a modified nucleoside analog,  $\beta$ -D-N<sup>4</sup>-hydroxycytidine, which was previously shown to be effective against hepatitis C virus (28) and human coronavirus (29) was found to inhibit CHIKV and VEEV replication in cell culture suggesting that employing nucleoside analogs for alphaviral alleviation is a rewarding approach (30, 31).

In this study, a non-radioactive capillary electrophoresis (CE)-based assay has been developed that measures the MTase activity of the alphaviral nsP1 capping enzyme independently of its GT activity. To achieve this, VEEV nsP1 (full-length) and a C-terminal truncated construct of CHIKV nsP1 were cloned, recombinantly expressed and purified. Using this CE-based assay, the influence of various reaction parameters on the methylation reaction of VEEV and CHIKV nsP1 enzyme was determined. H37A mutant of VEEV nsP1 was designed and used to examine the formation of m<sup>7</sup>GTP during the alphaviral capping reaction using a different CE method. Additionally, the assay was used to characterize known inhibitors of alphavirus nsP1, sinefungin and aurintricarboxylic acid (ATA). Using this assay, the possibility of using adenosine analogs for modulation of nsP1 MTase activity was investigated. One of the compounds was found to inhibit the MTase activity of both VEEV and CHIKV nsP1. The adenosine analog inhibitor identified using this assay was also validated for nsP1 inhibition using an orthogonal non-radioactive enzyme-linked immunosorbent assay (ELISA) assay. Further, the antiviral efficacy of the identified inhibitor was evaluated in vitro using cell-based assays. Intriguingly, the compound showed significant inhibition of CHIKV in cell culture-based studies, asserting the reliability of the developed assay. This novel CE-based MTase assay and new approach of using adenosine analogs to target alphavirus nsP1 may promote the identification of novel therapeutics against alphaviruses.

# **MATERIALS AND METHODS:**

#### Cell line, virus strain and compounds:

Vero cells were procured from National Centre for Cell Science (NCCS), Pune, India and were maintained at 37°C with 5% CO<sub>2</sub> in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% inactivated FBS (Gibco, USA). A recent clinical isolate of CHIKV (strain no.:119067; GenBank: KY057363.1) was propagated in Vero cells using standard viral adsorption techniques, quantified by standard plaque assays and stored at -80°C (32, 33). SAM, SAH, GTP, UMP, caffeine, sinefungin, ATA, and m<sup>7</sup>GTP were purchased from Sigma. 2-Chloroadenosine, 3-Deazaadenosine, and 3-Deazaneplanocin A were from cayman chemicals and dissolved in 100% dimethyl sulfoxide (DMSO). 5-Iodotubercidin (5-IT), also a product of cayman chemicals was supplied in 100% ethanol.

# Cloning, expression, and purification of CHIKV nsP1 and VEEV nsP1:

For cloning of VEEV nsP1 (amino acid residues 1-535), PCR amplified DNA containing the VEEV nsP1 gene, which was a kind gift from Richard J. Kuhn (Purdue University, IN, USA), was taken as a template for PCR amplification. PCR amplification was done with primer pair: sense, 5'- GATTCCATATGGAGAAAGTTCACGTTGACATCGAGGAA-3'; and antisense, 5'-GCAT CTCGAGTTAGGCCCCAGCCTCTTGTAACATCAA-3'. VEEV nsP1 gene was then ligated in-frame with a hexa-histidine tag at N-terminal in a pET-28c plasmid. Positive clones were subsequently transformed into expression host Rosetta and the culture was grown overnight in terrific broth supplemented with kanamycin and chloramphenicol at 37°C and was used as an inoculum for a 1000 ml secondary culture. This secondary culture was grown at 37°C till OD<sub>600</sub> reached 0.4 and was then shifted to 18°C. At 0.7 OD<sub>600</sub> the cultures were induced with 0.4 mM isopropyl  $\beta$ -D-1-thiogalactopyranoside (IPTG) and were allowed to grow for another 16 h at 18°C. Cells were harvested after incubation by centrifugation and analyzed using 12% SDS-PAGE. MTase/GT mutants were generated using the PCR-based method for site-directed mutagenesis using specific primers. CHIKV nsP1 (amino acid residues 1-509) was cloned and purified as described previously (16).

The cell pellet harvested from bacterial culture was resuspended in 50 ml binding buffer (50 mM Tris buffer, pH 7.3, 20 mM imidazole, and 100 mM KCl). 1 mM phenylmethylsulfonyl fluoride (PMSF), 100 µl Halt protease inhibitor (Thermo Fisher Scientific, US), and 0.01 mg/ml

DNase (Promega, US) were added to the resuspended cell pellet. Cell pellet was incubated at 4°C for 10 min and was lysed using a French press system (Constant Systems Ltd, Daventry, UK). The cell lysate was centrifuged to separate insoluble cellular debris from soluble fraction containing recombinant protein. The clarified supernatant was loaded onto nickel-nitrilotriacetic acid (Ni-NTA) beads (Qiagen, USA) in a gravity flow column and incubated for 30 min at 4°C and flowthrough was collected. Column was washed with buffers containing increasing concentrations of imidazole. Recombinant nsP1 protein was eluted with 250 mM imidazole in 50 mM Tris buffer, pH 7.3, and 100 mM KCl. Different fractions were analyzed using 12% SDS-PAGE. The identity of the protein was checked with matrix-assisted laser desorption-time of flight spectrometer (MALDI-TOF) after digestion with trypsin. Fractions containing recombinant protein were mixed and dialysed against dialysis buffer (50 mM Tris buffer, pH 7.0, 20 mM KCl, 2 mM DTT, and 2.5 mM MgCl<sub>2</sub>). VEEV nsP1 (H37A and D63A) mutants were expressed and purified with Ni<sup>+2</sup> affinity chromatography similar to the expression and purification of the wild type (wt) protein. The dialysed protein was frozen in liquid nitrogen and stored at -80°C. The protein was thawed when needed and concentrated to the required concentration with amicon centrifugal filters (Millipore, USA).

# **CE** methods

The products of the nsP1 MTase reaction are SAH and m<sup>7</sup>GTP. In this study, two distinct methods for the detection of SAH and the detection of m<sup>7</sup>GTP have been developed. Detection of SAH was performed with a fused-silica capillary whilst poly-vinyl alcohol (PVA)-coated capillary was used for the detection of m<sup>7</sup>GTP.

## Method 1: Fused-silica capillary

CE analysis was done using an Agilent 7100 CE system (Agilent Technologies, USA) fitted with a diode-array detector (DAD) detection system. The electrophoretic separation for SAM and SAH was done using an extended light path fused-silica capillary [64.5 cm (56 cm effective length) X 50 µm internal diameter]. The sample was injected hydrodynamically by applying pressure of 50 mbar for 10 s using autosampler followed by application of 30 kV voltage for separation of analytes. The capillary was thermostated at 20°C. The sample vials were stored in a sample tray at 8°C. Detection was done with a DAD coupled to a UV detection system at the cathodic end of the capillary at the wavelength of 260 nm. At the beginning of each day, capillary was conditioned using the following sequence: (i) 5-min rinse with CE-grade water (ii) 10-min

rinse with NaOH, (iii) 5-min rinse with water, and (iv) 10 min rinse with running buffer. Between two runs, the capillary was rinsed for 100 s with running buffer. At the end of each day, the capillary was flushed for 5 min with water and subsequently for 5 min with  $N_{2}$ , and was taken out of the instrument.

## Method 2: PVA capillary

For examining the formation of m<sup>7</sup>GTP by H37A mutant, PVA-coated capillary (Agilent Technologies, USA) [64.5 cm (56 cm effective length) X 50 µm internal diameter] was employed. The coating on the capillary suppresses electro-osmotic flow drastically and reverse voltage polarity was applied across the ends of the coated capillary to facilitate the rapid migration of negatively charged species such as GTP. The capillary was thermostated at 20°C. The sample vials were stored in a sample tray at 8°C. To achieve baseline separation of the product m<sup>7</sup>GTP, a voltage of 30 kV was applied. The sample to be analyzed was introduced hydrodynamically in the capillary using 50 mbar pressure for 10 s using autosampler. PVA capillary was flushed with water for 200 s and buffer with 200 s prior to the first run of the day. Between two successive runs, capillary was rinsed with the running buffer for 100 s. 254 nm wavelength was used for the detection and quantification of the analytes.

#### **MTase reaction**

MTase reaction was carried out in a final reaction volume of 20 µl in 50 mM Tris buffer, pH 7.0, 1 mM DTT, 10 mM/20 mM KCl, 4 mM GTP or GIDP (Guanosine 5'-[ $\beta$ , $\gamma$ -imido]triphosphate), 0.3 mM SAM, and 20 µM of VEEV nsP1/10 µM CHIKV nsP1 and incubated at 30°C. For detection of m<sup>7</sup>GTP using the H37A mutant of VEEV nsP1, MTase reaction was the same except increased concentration of SAM (1 mM) was used in the reaction owing to the higher detection limit of m<sup>7</sup>GTP. MTase reaction was also done with the D63A mutant of VEEV nsP1 to be used as a negative control. For following the time-course study, reaction was stopped at different time points by adding acetonitrile in 1:2 (vol/vol) ratios. The mixture was vortex-mixed for 15 s and protein was precipitated for 20 min at 12,000 rpm. Supernatant was transferred to sample vials for CE analysis. All reactions were done in duplicate.

## **CE-based nsP1 inhibition assays**

The compounds were dissolved in DMSO and 5-IT was dissolved in ethanol. Typical inhibition assay reaction was carried out in reaction volume of 20 µl in 50 mM Tris buffer, pH 7.0,

1 mM DTT, 10 mM KCl, 4 mM GTP or GIDP, 0.3 mM SAM, and 20  $\mu$ M of VEEV nsP1 or 10  $\mu$ M CHIKV nsP1. Sinefungin and ATA were tested at 7 different concentrations around reported half-maximal inhibitory concentration (IC<sub>50</sub>) value of each for VEEV nsP1(34). The reaction mixture was incubated at 30°C for 2 h. 3-Deazaneplanocin A, 2-Chloroadenosine, 3-Deazaadenosine, and 5-IT were tested at a 50  $\mu$ M concentration. Control reaction mixtures were incubated along with inhibition assays containing corresponding vehicle concentration.Each compound was tested in duplicate.

## nsP1 ELISA based assay:

GT reaction was performed in 50 mM Tris buffer pH 7.3, 5 mM DTT, 10 mM NaCl, 2 mM MgCl<sub>2</sub>, 5 mM DTT, 100 µM GTP, 100 µM SAM with 20 µM protein at 25°C for 30 min. Detection of CHIKV nsP1 GT activity was done with an ELISA assay as reported earlier (16). Briefly, reaction mixtures were transferred to 96 well high binding ELISA plate (Greiner Bio-One) after the reaction was stopped by the addition of an equal volume of 2% SDS and 5 mM EDTA followed by incubation for 1 h at 25°C. Wells were washed twice with TBST buffer (20 mM Tris pH 7.5, 150 mM NaCl, 0.1% Tween-20), blocked in 3% skim milk in TBST for 1 h, washed again and incubated at 25°C for 1 h with 1:5000 anti-m7G cap monoclonal antibody (Merck). Subsequently, 1:10,000 HRP-conjugated anti-mouse IgG1 secondary antibody (Affymetrix eBioscience) was added to the wells and incubated at 25°C for 1 h after washing with TBST. Finally, for the detection of immunoreactive protein, 100 µL of TMB/H<sub>2</sub>O<sub>2</sub>-ELISA substrate (GeNei) was added to each well of the plate, incubated and the reaction was stopped by the addition of an equal volume of 1 N H<sub>2</sub>SO<sub>4</sub> after colour development. The absorbance readings at 450 nm were obtained using multi-mode plate reader Cytation 3 (BioTek Instruments, Inc.). The inhibitor was added to the reaction mixture and subjected to the ELISA procedure as described. Wells containing reaction mixture with vehicle control were used as positive control while cells without protein were taken as background control. Each concentration was tested in duplicate.

#### Data analysis

Standard curves for SAH and m<sup>7</sup>GTP were obtained by plotting the corrected peak areas of SAH and m<sup>7</sup>GTP against their concentration. Peak integration and data acquisition were done using the Agilent CE Open Lab analysis software associated with the instrument. The corrected peak area of SAH was taken by subtracting the peak area obtained in the blank assay which

contains all the components of reaction mixture except the enzyme. The progress of the reaction was quantified as the increase in the area of the peak corresponding to SAH. Internal standards were used to compensate for the variability arising due to differences in injection volume. It also takes care of minor fluctuations in migration time between different CE runs. Internal standard improves the precision in quantification of the analyte and acts as a standard for corrected migration time. Caffeine was used as an internal standard to assess the product formation by normalizing the value of peak area of SAH against the peak area of caffeine while UMP was used to normalize the m<sup>7</sup>GMP peak area.

Data values were normalized with peak area of the internal standard for each run. The average of two duplicate readings and standard deviations were calculated using Microsoft Excel. Percentage inhibition was calculated using the following equation:

inhibition% = 
$$100 - (\frac{x}{blank} X 100)$$

Where x is the corrected peak area of the product in the presence of inhibitor while blank is the peak area when only the substrate is present in the reaction mixture.  $IC_{50}$  values of sinefungin and ATA were calculated using GraphPad Prism® software. Non-linear regression was used for curve fitting and equation for the sigmoidal dose-response (variable slope) was used to interpolate values for determining  $IC_{50}$  values.

#### **Cell viability assay:**

Cytotoxicity of 5-IT was determined in Vero cells prior to the evaluation of its antiviral efficacy. Standard MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5-Diphenyltetrazolium Bromide) assay was used to assess the cell viability profile of 5-IT against Vero cells. Briefly, Vero cells were seeded in a 96-well plate and incubated overnight for attachment. The next day, cells were treated with different concentrations of 5-IT along with 0.1% ethanol as the positive control. Cells were incubated for 24 h prior to the addition of MTT. Plates were then incubated for 4 h at 37°C followed by the addition of DMSO to dissolve the resulting formazon crystals. Finally, absorbance was measured at 570 nm using Cytation 3 multi-mode plate reader (BioTek Instruments, Inc.). Each concentration was tested in triplicate.

### Viral-yield reduction assay:

To evaluate the antiviral efficacy of the compound *in vitro*, plaque-reduction assay was performed to quantify the change in viral titer in the presence of compound. Vero cells were seeded in a 24-well plate and incubated overnight for attachment. When cells were 80% confluent, they were infected with CHIKV at MOI=1 along with varying concentrations of the compound in the DMEM medium with 2% FBS. After 24 h, supernatants of compound-treated/vehicle-treated cells were harvested and stored at -80°C. Viral-induced cytopathic effects (CPE) were observed with light microscope (Carl Zeiss, Germany) 48 hpi (hours post-infection). For time-of-addition studies, cells were pre-treated 2 h before infection with 0.75  $\mu$ M compound. Cell monolayer was washed with PBS and viral infection was done at an MOI of 1. For posttreatment and simultaneous-treatment of the cells, 5-IT was added to the media at 0, 1, 2, 3, 4 and 6 h post-infection. Cell culture supernatant was harvested at 24 h after infection for the determination of viral titer.

Titer determination was performed with conventional plaque-forming assay (35, 36). Briefly, 10-fold dilutions of different viral stocks were prepared in DMEM medium with 2% FBS and were used to infect cell monolayer for 1.5 h at 37°C. Infected cells were washed, overlaid with 1% carboxymethyl cellulose (CMC; Sigma) in Minimum Essential Medium (MEM) with 2% FBS and incubated for 48 h. Overlay media was removed and cells were fixed and stained with 10% formaldehyde-1% crystal violet solution for counting of plaques. Virus titer was indicated as plaque-forming units per millilitre (PFU/ml). Each concentration was tested in triplicate. Concentration at which compound is able to reduce viral titer by 50% compared to vehicle control (EC<sub>50</sub>) was calculated with GraphPad Prism (GraphPad Software, USA).

#### Immunofluorescence assay:

CHIKV-Infected monolayer of Vero cells was incubated in the presence of different concentrations of 5-IT for 36 h prior to being processed for indirect immunofluorescence assay. Monolayers of cells were fixed with acetone-methanol (1:1) for 15 min followed by washing with DPBS. Cells were subjected to 0.5% Triton-X-100 for 10 min to facilitate permeabilization and washed with DPBS. Cells were then incubated for 1 h with 1:250 mouse anti-alphavirus IgG<sub>2a</sub> monoclonal antibody that recognizes the alphavirus group surface antigen (Santa Cruz Biotechnology, Inc.) and were subsequently washed 3 times with DPBS before incubation for another 1 h in 1:500 goat anti-mouse secondary antibody conjugated with fluorescein isothiocyanate (FITC; Sigma). Cell nuclei were counterstained with 4',6-diamidino-2-phenylindole

(DAPI). Image acquisition was done on EVOS FL imaging system (Thermo Fisher Scientific) using both DAPI and GFP channels. Images were processed by EVOS FL software.

# Quantitative reverse transcription polymerase chain reaction (qRT-PCR):

To quantify the intracellular viral RNA, cells were treated with the compound as described in the above-mentioned section. Cells were lysed and RNA was extracted using Trizol as described in the manufacturer's instructions. Subsequently, cDNA was generated using M-MLV Reverse Transcriptase (Promega, USA), random hexamers, and 1  $\mu$ g of RNA as recommended by the manufacturer. Reverse-transcribed DNA was used to amplify actin and viral E1 genes employing KAPA SYBR fast universal qPCR kit on Quantstudio real-time PCR system (Applied Biosystems, Carlsbad, CA) following manufacturer's protocol. The primer sequences used were as follows: E1 forward: 5'-AAGTACACTGTGCAGCTGAGT-3'; E1 reverse: 5'-GCATAGCACCACGATTAGAATC-3'; actin forward: 5'-ATTGCCGACAGGATGCAGAA-3' and actin reverse: 5'-GCTGATCCACATCTGCTGGAA-3' (IDT, USA). Melting curve analysis was performed to ascertain the specificity of the product.  $\Delta\Delta$ Ct method was used for the relative quantification of actin and E1, and the experiment was undertaken in triplicate.

# RESULTS

## nsP1 purification:

VEEV nsP1 gene was cloned in *E.coli*. with a fused hexa-histidine tag at the N-terminus and the construct was confirmed by Sanger sequencing. The recombinant protein was purified to homogeneity using Ni-NTA affinity chromatography. H37A and D63A, the two mutants of VEEV nsP1 were generated by site-directed mutagenesis and recombinant proteins were purified using the same protocol for enzymatic characterization (Fig. 1A). Purified protein samples were analyzed on 12% SDS-PAGE gel for homogeneity (Fig. 1B and C). The identity of purified VEEV nsP1 wt protein was further confirmed by MALDI-TOF after trypsin digestion (data not shown). A C-terminal truncated form of CHIKV nsP1 (residues 1-509), which has been recently characterized by our laboratory was also purified (16). The MTase enzymatic activity of purified nsP1 proteins from VEEV and CHIKV was characterized using the developed non-radioactive CE-based method.

# Figure 1

#### **Optimisation of CE running conditions**

Running buffer or background electrolyte (BGE) was optimised to achieve good separation of analytes for performing CE-based nsP1 MTase assay. The main purpose was to resolve the SAM and SAH peaks. SAM is a substrate and SAH is one of the products in the MTase reaction of nsP1. In the initial trials to resolve analytes, 50 mM phosphate buffer, pH 2.5, 200 mM glycylglycine buffer, pH 8.4, 20 mM Tris buffer, pH 7.0, and 150 mM phosphate buffer, pH 1.5 were tried out before using 50 mM borate buffer, pH 9.3 as the BGE. CE runs with buffers other than borate suffered from either poor baseline separation, peak broadening or current leakage during each run. Complete separation of SAM and SAH was achieved with the use of borate buffer. Additionally, the two diastereomeric forms of SAM (*S*,*S* and *R*,*S*) were distinguished from each other during CE analysis (Fig. 2). Furthermore, injection parameters namely, injection mode (electrokinetic or hydrodynamic injection), pressure, time, and running voltage were optimised as hydrodynamic pressure injection with 50 mbar pressure for 10 s and 30 kV running voltage (normal polarity).

CE run using borate buffer alone was able to achieve complete baseline separation of SAM and SAH but suffered from poor migration time reproducibility. Addition of an organic modifier (acetonitrile) as an additive to the BGE enhanced both the resolution and migration time reproducibility of the peaks. Methanol was also tested as an organic modifier but could not improve the reproducibility of migration time. The percentage of acetonitrile in the separation buffer was optimised to 10% to strike a balance between migration time and resolution. The other substrate, GTP, could not be detected within 11 min of CE run time under the given CE running conditions (Fig. 2).

When reaction buffer was injected without deproteinization of the reaction mixture, protein components adhered to the capillary wall affecting migration time in the subsequent runs. Using trichloroacetic acid for deproteinization of the reaction mixture resulted in peak deformation essentially due to a change in matrix component because of low pH. Therefore, acetonitrile (2:1, v/v) was used to precipitate protein before injecting it for analysis by CE. Acetonitrile in the sample buffer gives rise to transient pseudo-isotachophoresis where the salt acts as a leading ion, and acetonitrile functions as a terminating ion to provide the high field strength for sample

concentration and band sharpening improving the overall separation efficiency (42, 43). Under these analysis conditions, we could detect SAH in concentrations as low as 0.5  $\mu$ M using extended light path fused-silica capillary.

We also optimised the BGE and separation parameters for CE analysis of products of MTase reaction of H37A VEEV nsP1 mutant using PVA-coated capillary. We evaluated the efficiency of various concentrations of MES buffer, pH 6.4 for separating m<sup>7</sup>GTP from other reaction components in the MTase assay reaction mixture. m<sup>7</sup>GTP could be identified in the reaction mixture using 75 mM MES buffer as BGE and using the injection and running parameters mentioned in the methodology section. 75 mM MES buffer offered baseline separation of the product, m<sup>7</sup>GTP from proteic material and remaining GTP or GDP present in the reaction mixture.

The two CE methods were validated for SAH and m<sup>7</sup>GTP detection under the optimized CE analysis conditions with respect to limit of quantitation, RSD of migration time and linearity (Table 1). Calibration curves of the analytes (SAH and m<sup>7</sup>GTP) were generated using different concentrations of the analytes. With the use of internal standards, linearity of the calibration curve for corrected migration time ( $R^2$ ) of SAH was found to be 0.9998 while for m<sup>7</sup>GTP detection using PVA coated capillary, the  $R^2$  for corrected migration time was calculated to be 0.9865.

Table 1

# Figure 2

## **Optimisation of reaction conditions for MTase activity**

For preliminary characterization of the MTase reaction using the CE-based method, VEEV nsP1 (full-length) and C-terminal truncated CHIKV nsP1 were incubated at different concentrations with the reaction mixture for different time periods. Enzyme activity for VEEV nsP1 (20  $\mu$ M) in 30 min and CHIKV nsP1 (10  $\mu$ M) could be detected in 45 min using 300  $\mu$ M SAM. Methyl acceptor GTP was included in the reaction at a saturated concentration (4 mM).

Lower concentrations of enzymes/substrates did not yield detectable product within the assay time. This concentration of enzyme and substrates were used for all subsequent experiments. Next, the MTase activity of VEEV nsP1 and CHIKV nsP1 was assayed for determining the optimal reaction parameters viz. pH, magnesium ion concentration, temperature and salt (KCl) concentration.

The analysis for the temperature dependence of alphavirus nsP1 MTase activity demonstrated a bell-shaped profile for the temperature dependence of the activity with maximum activity at 30°C (Fig. 3A). Next, for determining the pH maximal of the MTase activity of VEEV nsP1 and CHIKV nsP1, activity was performed at pH ranging from 6.5 to 8.5. Both the enzymes showed a pH maximal corresponding to physiological pH i.e. 7 (Fig. 3B). Thus, the MTase reaction is favoured at physiological conditions that mimic the cellular environment inside the host cell where viral RNA capping takes place.

For CHIKV nsP1, increasing the concentration of KCl in the final assay buffer to 50 and 100 mM had a negligible effect on the MTase activity. Above 100 mM KCl there was a steep reduction in enzymatic activity for both VEEV and CHIKV nsP1 (Fig. 3C). The MTase activity of VEEV and CHIKV nsP1 as a function of magnesium concentration was evaluated using the CE method. A gradual decline in the enzymatic activity with an increase in Mg<sup>+2</sup> ion concentration was observed (Fig. 3D). This observation is in agreement with the earlier findings reported for alphaviral nsP1 that the enzyme does not require magnesium ions for its MTase activity (34, 44, 45). Taken together, under the conditions employed in the enzymatic assay, VEEV and CHIKV nsP1 exhibited the highest enzymatic activity at pH 7.0, at KCl concentration 10/20 mM, and at 30°C in the absence of magnesium ion.

# Figure 3

# **Time-course MTase reaction**

A time-course experiment where GTP was taken as the methyl acceptor in the presence and absence of magnesium ion was performed with optimal buffer conditions. Intriguingly, it was observed that in the absence of metal ion the MTase reaction with GTP proceeds linearly for 2 h as the SAH formation showed a linear range. In contrast, when magnesium ion, which acts as a cofactor in the subsequent GT reaction, was present, the progress curve became non-linear after 1 h (Fig. 4A). It is speculated that the subsequent GT reaction that guanylate nsP1 might affect the activity of the enzyme by product inhibition. Hence, to decouple the MTase and GT reactions catalysed by the same enzyme, a non-hydrolyzable analog of GTP with a  $\beta$ - $\gamma$  nonhydrolyzable bond, GIDP was used (Fig. 4B and C). The use of GIDP excludes the possibility of the guanylylation of nsP1 that can interfere with the linearity of SAH formation over the reaction time. Thus, for subsequent assay development and testing of inhibitors GIDP was used instead of GTP as the methyl acceptor and the reaction time was maintained at 2 h. A typical electropherogram of the MTase nsP1 reaction assay mixture at different time points is shown in figure 2. nsP1 mutant D63A (MTase-deficient) of VEEV nsP1 was taken as a negative control and no increase in peak area corresponding to SAH with time in the MTase reaction mixture was observed.

#### Figure 4

## Identification of m<sup>7</sup>GTP using H37A VEEV nsP1 mutant

H37A mutant of nsP1 has been shown to be deficient in the formation of nsP1-m<sup>7</sup>GMP intermediate covalent complex by nsP1 GT enzyme reaction (Li et al., 2015). To further characterize the molecular mechanism of RNA capping reaction by alphaviral nsP1, the formation of m<sup>7</sup>GTP by mutant protein was analyzed. To achieve this, H37A mutation was engineered in VEEV nsP1 and purified H37A mutant was used for enzyme characterization. It was hypothesized that the m<sup>7</sup>GTP which is otherwise formed transiently during the nsP1 capping reaction and covalently attaches itself to the alphavirus nsP1 protein as m<sup>7</sup>GMP moiety, could be observed in the reaction mixture when the MTase reaction is carried out with H37A mutant. The formation of m<sup>7</sup>GTP was analyzed with the help of a PVA-coated capillary using reverse voltage polarity at the capillary ends (Fig. 5A). Reaction samples were also spiked with m<sup>7</sup>GTP for positive identification of the product. UMP was taken as the internal standard during m<sup>7</sup>GTP analysis. Time-course reaction with H37A mutant in the presence of SAM and GTP showed a linear formation of m<sup>7</sup>GTP over a 150 min period (Fig. 5B). The peak corresponding to m<sup>7</sup>GTP was absent when 10  $\mu$ M sinefungin or 100  $\mu$ M ATA was added to the MTase reaction mixture further confirming that the H37A mutant of nsP1 indeed produced m<sup>7</sup>GTP.

# Figure 5

## Inhibition of VEEV and CHIKV nsP1 MTase activity:

To validate the established assay for SAH detection, inhibition efficiency of two known inhibitors of nsP1, sinefungin and ATA, was evaluated against nsP1 (from VEEV and CHIKV), and their respective IC<sub>50</sub> values for both the enzymes were calculated (Fig. 6). Sinefungin and ATA are known inhibitors of VEEV nsP1. IC<sub>50</sub> values of sinefungin and ATA for VEEV nsP1 and CHIKV nsP1 are shown in table 2. The IC<sub>50</sub> values of sinefungin and ATA calculated by the CEbased nsP1 MTase assay are very similar to the ones reported earlier (34). The observed slight differences in the IC<sub>50</sub> values of sinefungin and ATA for VEEV nsP1 can be attributed to the differential folding of the protein owing to the different purification protocols or the different concentrations of substrates used in CE-based assay. This validates the utility of the CE-based nsP1 MTase assay for screening inhibitors against alphaviral nsP1 MTase. The inhibition efficiency of these two inhibitors has not been evaluated for MTase activity of CHIKV nsP1 previously.

# Table 2

# Figure 6

Using the developed CE-based nsP1 MTase assay, a few adenosine analogs were evaluated for their potency to inhibit the MTase enzyme activity of VEEV nsP1 and CHIKV nsP1. A fixed (50  $\mu$ M) concentration of each inhibitor candidate: 2-Chloroadenosine, 3-Deazaadenosine, 3-Deazaneplanocin A, and 5-IT was used to assess their nsP1 inhibition efficiency. Among the compounds tested against nsP1, only 5-IT showed effective inhibition of the nsP1 enzyme (Fig. 7A). An indirect ELISA assay was also performed which measures the m<sup>7</sup>GMP-nsP1 adduct formation. It detects m<sup>7</sup>GMP covalently bound to the nsP1 protein formed as a result of the GT activity of nsP1 using anti-m<sup>7</sup>-GMP antibodies (16). This assay also showed a concentrationdependent reduction in CHIKV nsP1 GT activity in presence of the inhibitor with an IC<sub>50</sub> value of 11.25  $\mu$ M confirming CHIKV nsP1 GT activity inhibition by 5-IT (Fig. 7B). **Figure 7** 

# Anti-CHIKV activity of 5-IT

The effect of 5-IT on cell viability was examined on Vero cells. 5-IT exerted a weak cytotoxic effect on cells at concentrations above 2  $\mu$ M at 24 h (Fig. 8A). To remove the possibility

of 5-IT mediated cytotoxicity, concentrations below 1.5  $\mu$ M were used for investigating the antiviral activity of 5-IT. To test the *in vitro* antiviral efficacy of 5-IT, CHIKV-infected cells were grown in the presence of varying concentrations of 5-IT for 24 h and viral titers were quantified using plaque-forming assay. 5-IT displayed significant inhibition of infectious progeny virus with an EC<sub>50</sub> of 0.409  $\mu$ M (Fig. 8B). 5-IT exhibited compound-mediated inhibition of CHIKV-induced CPE which were monitored 48 h after infection (Fig. S1). Anti-CHIKV activity of 5-IT was further confirmed by CHIKV immunostaining assay. Anti-alphavirus antibody was used to evaluate CHIKV reduction in cell culture in the presence of 5-IT. Fluorescence was barely detectable in infected cells treated with 1  $\mu$ M compound as compared to untreated cells confirming the reduction of CHIKV antigen expression in the treated cells (Fig. 8C).

The ability of 5-IT to inhibit viral RNA inside the infected cells was assessed by qRT-PCR. Treatment of infected cells with the compound led to a dose-dependent reduction in the intracellular viral RNA relative to mock-treated cells. Viral RNA was gradually reduced in treated cells above 0.5  $\mu$ M concentration of the compound and an approximately 9-fold reduction was observed at 1  $\mu$ M (Fig. 8D and E). This complements the data from plaque-reduction assay. Taken together, the results of plaque-reduction assay, qRT-PCR, and immunofluorescence indicate that 5-IT inhibits CHIKV replication in cell culture.

To identify the stage of viral replication affected by 5-IT, it was added to the infected cell monolayer at different time points. Pre-treatment of the cells with 5-IT showed minimal inhibitory effect against CHIKV infection. Addition of the compound at 4 hpi or 6 hpi did not show a marked reduction of CHIKV viral titer. 5-IT was most efficient when added 0-2 hpi suggesting that it inhibits an early, post-entry step of the viral replication cycle. The time-dependence of the antiviral efficiency of the compound is in agreement with its anti-nsP1 activity (1).

# Figure 8

# DISCUSSION

Alphaviruses use an unconventional mechanism of RNA capping, distinct from their host counterpart where the transfer of methyl group from SAM to GTP occurs before the transguanylation step (transfer of GTP to RNA). Alphavirus capping enzyme, nsP1 adds a type 0 cap structure at 5'-end of the nascent RNA (8). As RNA capping is a critical point in the viral life

cycle, nsP1 is a promising candidate for the development of therapeutic intervention against alphaviruses. MTase activity of recombinant nsP1 has been demonstrated with nsP1 from different alphaviruses including SINV and VEEV (34, 45). Previous efforts to detect MTase activity of nsP1 were based on the detection of radioactive product which albeit are sensitive and more reliable than their alternatives, are time-consuming and cumbersome. Radiolabels also cause environmental, health, cost, waste and regulatory issues. Another drawback of using this technique is that the SAH produced during the reaction inhibits the activity of most SAM-dependent methyltransferases (MTases).

Recently, as an alternative to the radioactive assays, a number of colorimetric and fluorometric assays have been developed and commercialized for the characterization of MTase enzymes. These are coupled assays wherein the SAH generated in the MTase reaction is subsequently acted upon by other enzymes included in the assay mixture. The final products of these coupled assays are then quantified by colorimetric or fluorometric detection. The coupled-assay approach is indirect and circumvents the problem of SAH accumulation which can act as the potent inhibitor of the MTases (46–49). These enzyme assays, however, when used for inhibitor screening suffer from artefacts arising mainly because of the promiscuity of several compounds that interfere with the enzyme coupling system by off-target inhibition (50). Inhibitors identified through such a screening strategy require a secondary assay for hit validation before being considered for follow-up studies.

The CE method developed in this study holds several advantages such as simple sample preparation, low sample requirement, and low cost. It also eliminates the need for expensive and potentially hazardous radioactive materials. Moreover, the assay relies on the direct detection of SAH generated in the MTase reaction thereby minimising any possible interference from inhibitor compounds. This reported assay allows the rapid detection of MTase activity of nsP1 capping enzyme. Whole CE analysis takes 13 min including the buffer run between two runs and multiple samples can be analyzed at once with an automated injection procedure without any manual intervention in between consecutive runs. This assay can be used for batch screening of inhibitors and can be modified and adapted for fully automated in-line CE assays. Separation of m<sup>7</sup>GTP from the reaction mixture of H37A mutant using PVA capillary has been demonstrated in this study. Alanine substitution at this position disrupts the formation of the phosphamide bond between nsP1 and m<sup>7</sup>GMP and this supports the hypothesis that the alphaviral capping enzyme

methylates GTP before it is hydrolysed to GMP and transferred to the 5'-end of RNA unlike host capping enzymes (51).

nsP1, being an attractive drug target can be effectively perturbed to feed the drug discovery pipeline for anti-alphaviral therapeutics. Sequence alignment reveals that the putative MTase domain or "core region" of nsP1 [spanning from 28-259 amino acids in VEEV nsP1; (39, 40)] is highly conserved within the alphavirus superfamily. The capping enzymes of alphaviruses share a high level of sequence homology and thus, the development of nsP1 inhibitors can warrant panalphavirus therapeutics. Moreover, viruses from alphavirus-like superfamily which includes several plant and animal viruses such as bamboo mosaic virus, brome mosaic virus, tobacco mosaic virus, alfalfa mosaic virus, and hepatitis E virus carry out capping of viral RNA using a mechanism similar to nsP1 (52-56). This non-radioactive assay provides a robust and versatile platform for screening and identification of novel inhibitors against these viral capping enzymes and other similar SAM-dependent MTases. Developed CE-based assay for MTase activity of nsP1 is based on the general detection method of SAH formed during the MTase reaction of alphavirus nsP1. Under our assay conditions, SAH accumulation in the MTase reaction was linear for at least 2 h. This is in agreement with the reports on VEEV and for SINV nsP1 (34, 45). The same detection range was used for the characterization of inhibitors of nsP1. Out of the tested compounds, only 5-IT showed efficient inhibition of both VEEV and CHIKV nsP1 and was further taken up for cell culture-based viral inhibition studies.

5-IT is a derivative of tubercidin (7-deaza-adenosine) and a known adenosine kinase inhibitor. It has been shown to possess anti-tumor activity (57, 58). The antiseizure activity of 5-IT has been demonstrated *in vivo* (59). This compound is also being studied for its potential as a therapeutic agent to treat epilepsy using mice model (60, 61). The role of cellular kinases in alphavirus replication remains poorly understood. A recent study that profiled the cellular kinome following CHIKV infection found a number of kinases to be undergoing changes in terms of abundance or activity (62). To our knowledge, adenosine kinase was not implicated in CHIKV infection in this or any other study. Thus, host adenosine kinase seems to be not involved in alphavirus infection. Time-of-drug addition studies indicate that 5-IT affects an early, post-entry replication step of the viral life cycle. Though extensive studies are required to identify other possible cellular or viral targets of 5-IT, at this stage it is reasonable to believe that antiviral effects of 5-IT are most likely, at least partially, can be attributed to the inhibition of alphaviral nsP1. Further studies are also needed for screening and improving the inhibition potency of compounds similar to 5-IT. In the absence of the structure of nsP1, it is rather difficult to establish a structureactivity relationship (SAR). Thus, at this point of time, we are not able to conjecture the interaction of different moieties of the compound with specific amino acid residues of nsP1. Chemical modification by addition or removal of chemical moiety/moieties may result in enhanced potency of 5-IT in terms of increased efficacy and improved pharmacokinetic properties. With the availability of the structure of nsP1 from the alphavirus genus, an extensive structureactivity study of 5-IT will be required to use it as a reference compound for rational drug designing and identification/development of more potent and specific therapeutic agents targeting nsP1 protein.

In conclusion, a simple, robust and versatile CE-based assay for measuring MTase activity of VEEV and CHIKV nsP1 was developed. Favourable assay parameters for MTase activity of VEEV and CHIKV nsP1 viz pH, temperature, salt concentration, and metal ion (Mg<sup>2+</sup>) concentration were optimised. For the mechanistic study of nsP1, m<sup>7</sup>GTP formation by H37A mutant of nsP1 was analyzed with the help of a PVA capillary using a separate CE method. The assay was further used to evaluate the IC<sub>50</sub> values of known nsP1 inhibitors, sinefungin and ATA. Evaluation of enzymatic activity in the presence of potential inhibitors led to the identification of adenosine analog 5-IT as the inhibitor of MTase activity of the enzyme. The potent hit compound was further evaluated in a secondary orthogonal ELISA assay that quantitates m<sup>7</sup>GMP-nsP1 adduct formed after nsP1 GT activity. 5-IT showed a marked reduction in CHIKV replication as evident by the results of the plaque-reduction assay, viral-induced CPE reduction, gRT-PCR, and IFA studies. The developed CE-based assay can further accelerate the screening of inhibitors against nsP1 of alphaviruses and identification or development of new antiviral drugs against alphaviruses. With the effective inhibition of CHIKVreplication in cell culture by 5-IT, the possible new approach of targeting alphaviral nsP1 with adenosine analogs can be further investigated for identification and development of pan-alphavirus antiviral agents.

# ACKNOWLEDGEMENTS

This work was supported by Science and Engineering Research Board, Department of Science and Technology, Government of India (EMR/2016/004938). RM is thankful to CSIR and SM is thankful to MHRD for financial support. Authors are indebted to Andrew S Miller at Purdue University, US for his help in MALDI-TOF experiments. Authors would also like to

acknowledge Mr. Ravi Kumar Marikanty, Mr. Jagmohan Singh and Mr. Nitin Vig from Agilent Technologies, India for technical assistance in CE analysis. The funders played no role in study design, data collection and analysis, the decision to publish, or the preparation of the manuscript.

# **AUTHOR CONTRIBUTION**

RM and SM conducted the experiments and analyzed the data. RM and ST planned experiments, analyzed the data and wrote the manuscript.

## REFERENCES

- Strauss JH, Strauss EG. 1994. The alphaviruses: gene expression, replication, and evolution. Microbiol Rev 58:491–562.
- Jose J, Snyder JE, Kuhn RJ. 2009. A structural and functional perspective of alphavirus replication and assembly. Future Microbiol 4:837–856.
- 3. Paessler S, Weaver SC. 2009. Vaccines for Venezuelan equine encephalitis. Vaccine 27:D80–D85.
- 4. Ehrenkranz NJ, Ventura AK. 1974. Venezuelan equine encephalitis virus infection in man. Ann Rev Med 25:9–14.
- 5. Powers AM, Logue CH. 2007. Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirus. J Gen Virol 88:2363–2377.
- Filipowicz W, Furuichi Y, Sierra JM, Muthukrishnan S, Shatkin AJ, Ochoa S. 1976. A protein binding the methylated 5'-terminal sequence, m7GpppN, of eukaryotic messenger RNA. Proc Nat Acad Sci 73:1559–1563.
- 7. Hyde JL, Diamond MS. 2015. Innate immune restriction and antagonism of viral RNA lacking 2'-O methylation. Virology 0:66–74.
- 8. Ahola T, Kääriäinen L. 1995. Reaction in alphavirus mRNA capping: formation of a covalent complex of nonstructural protein nsP1 with 7-methyl-GMP. Proc Nat Acad Sci 92:507–511.
- 9. Vasiljieva L, Merits A, Auvinen P, Kaariainen L. 2000. Identification of a novel function of the alphavirus capping apparatus-RNA 5'triphosphatase activity of Nsp2. J Biol Chem 275:17281-17287
- Wang H-L, O'rear J, Stollar V. 1996. Mutagenesis of the Sindbis virus nsP1 protein: effects on methyltransferase activity and viral infectivity. Virology 217:527–531.
- Ahola T, Lampio A, Auvinen P, Kääriäinen L. 1999. Semliki Forest virus mRNA capping enzyme requires association with anionic membrane phospholipids for activity. The EMBO journal 18:3164–3172.

- Laakkonen P, Ahola T, Kääriäinen L. 1996. The effects of palmitoylation on membrane association of Semliki forest virus RNA capping enzyme. J Biol Chem 271:28567–28571.
- Spuul P, Salonen A, Merits A, Jokitalo E, Kääriäinen L, Ahola T. 2007. Role of the amphipathic peptide of Semliki forest virus replicase protein nsP1 in membrane association and virus replication. J Virol 81:872–883.
- Bullard-Feibelman KM, Fuller BP, Geiss BJ. 2016. A Sensitive and Robust High-Throughput Screening Assay for Inhibitors of the Chikungunya Virus nsP1 Capping Enzyme. PLOS one 11:e0158923.
- Delang L, Li C, Tas A, Quérat G, Albulescu IC, De Burghgraeve T, Guerrero NS, Gigante A, Piorkowski G, Decroly E. 2016. The viral capping enzyme nsP1: a novel target for the inhibition of chikungunya virus infection. Sci Rep 6:31819.
- 16. Kaur R, Mudgal R, Narwal M, Tomar S. 2018. Development of an ELISA assay for screening inhibitors against divalent metal ion dependent alphavirus capping enzyme. Virus Res 256: 209-21.
- 17. Feibelman KM, Fuller BP, Li L, LaBarbera DV, Geiss BJ. 2018. Identification of small molecule inhibitors of the Chikungunya virus nsP1 RNA capping enzyme. Antiviral Res 154:124–131.
- 18. De Clercq E, Li G. 2016. Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev 29:695–747.
- 19. De Clercq E. 2011. A 40-year journey in search of selective antiviral chemotherapy. Annu Rev Pharmacol Toxicol 51:1–24.
- 20. De Clercq E. 2010. In search of a selective therapy of viral infections. Antiviral Res 85:19–24.
- 21. Brecher M, Chen H, Li Z, Banavali NK, Jones SA, Zhang J, Kramer LD, Li H. 2015. Identification and Characterization of Novel Broad-Spectrum Inhibitors of the Flavivirus Methyltransferase. ACS Infect Dis 1:340–349.
- Chen H, Liu L, Jones SA, Banavali N, Kass J, Li Z, Zhang J, Kramer LD, Ghosh AK, Li H. 2013. Selective inhibition of the West Nile virus methyltransferase by nucleoside analogs. Antiviral Res 97:232–239.
- 23. Jain R, Butler KV, Coloma J, Jin J, Aggarwal AK. 2017. Development of a S-adenosylmethionine analog that intrudes the RNA-cap binding site of Zika methyltransferase. Sci Rep 7:1632.
- 24. Vernekar SKV, Qiu L, Zhang J, Kankanala J, Li H, Geraghty RJ, Wang Z. 2015. 5'-Silylated 3'-1,2,3triazolyl Thymidine Analogues as Inhibitors of West Nile Virus and Dengue Virus. J Med Chem 58:4016–4028.
- 25. Delang L, Segura Guerrero N, Tas A, Quérat G, Pastorino B, Froeyen M, Dallmeier K, Jochmans D, Herdewijn P, Bello F, Snijder EJ, de Lamballerie X, Martina B, Neyts J, van Hemert MJ, Leyssen P.

This article is protected by copyright. All rights reserved

2014. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. J Antimicrob Chemother 69:2770–2784.

- Markland W, McQuaid TJ, Jain J, Kwong AD. 2000. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob Agents Chemother 44:859–866.
- 27. Julander JG, Bowen RA, Rao JR, Day C, Shafer K, Smee DF, Morrey JD, Chu CK. 2008. Treatment of Venezuelan equine encephalitis virus infection with (-)-carbodine. Antiviral Res 80:309–315.
- 28. Stuyver LJ, Whitaker T, McBrayer TR, Hernandez-Santiago BI, Lostia S, Tharnish PM, Ramesh M, Chu CK, Jordan R, Shi J, Rachakonda S, Watanabe KA, Otto MJ, Schinazi RF. 2003. Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. Antimicrob Agents Chemother 47:244–254.
- Pyrc K, Bosch BJ, Berkhout B, Jebbink MF, Dijkman R, Rottier P, van der Hoek L. 2006. Inhibition of human coronavirus NL63 infection at early stages of the replication cycle. Antimicrob Agents Chemother 50:2000–2008.
- 30. Ehteshami M, Tao S, Zandi K, Hsiao H-M, Jiang Y, Hammond E, Amblard F, Russell OO, Merits A, Schinazi RF. 2017. Characterization of β-d-N4-Hydroxycytidine as a Novel Inhibitor of Chikungunya Virus. Antimicrob Agents Chemother 61:e02395-16
- 31. Urakova N, Kuznetsova V, Crossman DK, Sokratian A, Guthrie DB, Kolykhalov AA, Lockwood MA, Natchus MG, Crowley MR, Painter GR, Frolova EI, Frolov I. 2018. β-d-N4-Hydroxycytidine Is a Potent Anti-alphavirus Compound That Induces a High Level of Mutations in the Viral Genome. J Virol 92:e01965-17.
- 32. Kaur R, Neetu null, Mudgal R, Jose J, Kumar P, Tomar S. 2019. Glycan-dependent chikungunya viral infection divulged by antiviral activity of NAG specific chi-like lectin. Virology 526:91–98.
- 33. Singh H, Mudgal R, Narwal M, Kaur R, Singh VA, Malik A, Chaudhary M, Tomar S. 2018.
   Chikungunya virus inhibition by peptidomimetic inhibitors targeting virus-specific cysteine protease.
   Biochimie 149:51–61.
- 34. Li C, Guillén J, Rabah N, Blanjoie A, Debart F, Vasseur J-J, Canard B, Decroly E, Coutard B. 2015.
   mRNA capping by Venezuelan Equine Encephalitis Virus nsP1: Functional characterization and implication for Antiviral Res. J Virol 89:8292-303.
- 35. Aggarwal M, Kaur R, Saha A, Mudgal R, Yadav R, Dash PK, Parida M, Kumar P, Tomar S. 2017. Evaluation of antiviral activity of piperazine against chikungunya virus targeting hydrophobic pocket of alphavirus capsid protein. Antiviral Res 146:102–111.
- 36. Sharma R, Fatma B, Saha A, Bajpai S, Sistla S, Dash PK, Parida M, Kumar P, Tomar S. 2016. Inhibition of chikungunya virus by picolinate that targets viral capsid protein. Virology 498:265–276.

- Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, Lopez R, McWilliam H, Remmert M, Söding J, Thompson JD, Higgins DG. 2011. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol 7:539.
- Gouet P, Robert X, Courcelle E. 2003. ESPript/ENDscript: extracting and rendering sequence and 3D information from atomic structures of proteins. Nucleic Acids Res 31:3320–3323.
- Ahola T, Karlin DG. 2015. Sequence analysis reveals a conserved extension in the capping enzyme of the alphavirus supergroup, and a homologous domain in nodaviruses. Biology direct 10:16.
- 40. Rozanov MN, Koonin EV, Gorbalenya AE. 1992. Conservation of the putative methyltransferase domain: a hallmark of the 'Sindbis-like' supergroup of positive-strand RNA viruses. J Gen Virol 73:2129–2134.
- Ahola T, Laakkonen P, Vihinen H, Kääriäinen L. 1997. Critical residues of Semliki Forest virus RNA capping enzyme involved in methyltransferase and guanylyltransferase-like activities. J Virol 71:392–397.
- 42. Friedberg MA, Hinsdale M, Shihabi ZK. 1997. Effect of pH and ions in the sample on stacking in capillary electrophoresis. J Chromatogra A 781:35–42.
- 43. Shihabi ZK. 1995. Sample stacking by acetonitrile-salt mixtures. J Capillary Electropho 2:267–271.
- 44. Laakkonen P, Hyvönen M, Peränen J, Kääriäinen L. 1994. Expression of Semliki Forest virus nsP1 specific methyltransferase in insect cells and in Escherichia coli. J Virol 68:7418–7425.
- 45. Tomar S, Narwal M, Harms E, Smith JL, Kuhn RJ. 2011. Heterologous production, purification and characterization of enzymatically active Sindbis virus nonstructural protein nsP1. Protein Express Purificat 79:277–284.
- 46. Dorgan KM, Wooderchak WL, Wynn DP, Karschner EL, Alfaro JF, Cui Y, Zhou ZS, Hevel JM.
  2006. An enzyme-coupled continuous spectrophotometric assay for S-adenosylmethionine-dependent methyltransferases. Anal Biochem 350:249–255.
- 47. Duchin S, Vershinin Z, Levy D, Aharoni A. 2015. A continuous kinetic assay for protein and DNA methyltransferase enzymatic activities. Epigenetics Chromatin 8:56
- 48. Ibáñez G, McBean JL, Astudillo YM, Luo M. 2010. An enzyme-coupled ultrasensitive luminescence assay for protein methyltransferases. Anal Biochem 401:203–210.
- 49. Schäberle TF, Siba C, Höver T, König GM. 2013. An easy-to-perform photometric assay for methyltransferase activity measurements. Anal Biochem 432:38–40.
- 50. Drake KM, Watson VG, Kisielewski A, Glynn R, Napper AD. 2014. A sensitive luminescent assay for the histone methyltransferase NSD1 and other SAM-dependent enzymes. Assay Drug Dev Technol 12:258–271.
- Decroly E, Ferron F, Lescar J, Canard B. 2012. Conventional and unconventional mechanisms for capping viral mRNA. Nat Rev Microbiol 10:51–65.

This article is protected by copyright. All rights reserved

- Kong F, Sivakumaran K, Kao C. 1999. The N-terminal half of the brome mosaic virus 1a protein has RNA capping-associated activities: specificity for GTP and S-adenosylmethionine. Virology 259:200–210.
- 53. Li YI, Chen YJ, Hsu YH, Meng M. 2001. Characterization of the AdoMet-dependent guanylyltransferase activity that is associated with the N terminus of bamboo mosaic virus replicase. J Virol 75:782–788.
- 54. Magden J, Takeda N, Li T, Auvinen P, Ahola T, Miyamura T, Merits A, Kääriäinen L. 2001. Virusspecific mRNA capping enzyme encoded by hepatitis E virus. J Virol 75:6249–6255.
- 55. Merits A, Kettunen R, Mäkinen K, Lampio A, Auvinen P, Kääriäinen L, Ahola T. 1999. Virus-specific capping of tobacco mosaic virus RNA: methylation of GTP prior to formation of covalent complex p126-m7GMP. FEBS Lett 455:45–48.
- 56. Vlot AC, Menard A, Bol JF. 2002. Role of the Alfalfa Mosaic Virus Methyltransferase-Like Domain in Negative-Strand RNA Synthesis. J Virol 76:11321–11328.
- Parkinson FE, Geiger JD. 1996. Effects of iodotubercidin on adenosine kinase activity and nucleoside transport in DDT1 MF-2 smooth muscle cells. J Pharmacol Exp Ther 277:1397–1401.
- Zhang X, Jia D, Liu H, Zhu N, Zhang W, Feng J, Yin J, Hao B, Cui D, Deng Y, Xie D, He L, Li B. 2013. Identification of 5-Iodotubercidin as a genotoxic drug with anti-cancer potential. PLoS one 8:e62527.
- Fedele DE, Gouder N, Güttinger M, Gabernet L, Scheurer L, Rülicke T, Crestani F, Boison D. 2005. Astrogliosis in epilepsy leads to overexpression of adenosine kinase, resulting in seizure aggravation. Brain 128:2383–2395.
- 60. Boison D. 2008. The adenosine kinase hypothesis of epileptogenesis. Prog Neurobiol 84:249–262.
- 61. Gouder N, Scheurer L, Fritschy J-M, Boison D. 2004. Overexpression of Adenosine Kinase in Epileptic Hippocampus Contributes to Epileptogenesis. J Neurosci 24:692–701.
- Broeckel R, Sarkar S, May NA, Totonchy J, Kreklywich CN, Smith P, Graves L, DeFilippis VR, Heise MT, Morrison TE, Moorman N, Streblow DN. 2019. Src Family Kinase Inhibitors Block Translation of Alphavirus Subgenomic mRNAs. Antimicrob Agents Chemother 63:e02325-18.

# **Figure Legends**

**FIG 1 Alphaviral nsP1 sequence comparison and purified recombinant nsP1.** (A) Sequence alignment of nsP1 from different alphaviruses was done using Clustal Omega (37). Graphical output was generated

using ESPript (38). The conserved region from 29- 259 amino acids (amino acid residues in VEEV nsP1) referred to as the "core" region based on sequence homology is considered as the putative MTase-GTase domain (39, 40). The region spanning ~200 amino acids downstream of this core region is also essential for nsP1 MTase and GTase activities (10, 12, 41). Invariable residues are shown in red background while similar residues are in yellow background. Asp-63 and His-37 of VEEV nsP1, vital for MTase and GT activities respectively were mutated in this study and are denoted with  $\blacktriangle$  under them. RRV, Ross River virus; SFV, Semliki Forest virus; ONNV, O'nyong-nyong virus. (B) and (C) SDS-PAGE analysis of purified recombinant VEEV and CHIKV nsP1.

**FIG 2 Typical electropherogram of nsP1 MTase reaction products.** Overlay of CE-electropherograms obtained for MTase enzymatic activity of VEEV nsP1 at indicated time points (0 h, 0.5 h, 1 h, and 2 h). MTase reaction was performed with reaction conditions as discussed in the methodology section. The separation was performed in borate buffer, pH- 9.3 with 10% acetonitrile; pressure injection with 50 mbar for 10 s; applied voltage: 30 kV; extended light path fused-silica capillary, 64.5 cm length (56 cm to the detector) and 50 µm internal diameter. Black stars indicate the SAH peak. Absorbance was measured at 260 nm. IS: internal standard (caffeine).

**FIG 3 Determination of optimal MTase reaction conditions for VEEV (•) and CHIKV nsP1 (■).** The optimal MTase reaction conditions were determined by individually varying (A) temperature, (B) pH, (C) KCl concentration, and (D) magnesium ion concentration while the other three parameters were kept at optimal levels. Activity was calculated as an increase in the corrected peak area of SAH in the CE-electropherogram. For each parameter, the optimal activity observed was taken as 100% and the relative activity was calculated at other conditions. Data points represent mean values and error bars are standard deviations from duplicate experiments.

FIG 4 Time-course of the MTase reaction of VEEV and CHIKV nsP1. (A) A 6-point calibration curve was generated to demonstrate the linearity of SAH detection using optimized CE method. Corrected peak area plotted against concentrations of SAH show a linear curve in the concentration range 2-200  $\mu$ M. Effect of magnesium in the reaction buffer on the linearity of product formation was assessed. Reaction progression was measured by the increase in corrected peak area of SAH with caffeine as the internal standard. MTase reaction was carried out with SAM as the methyl donor and GIDP or GTP as the methyl group acceptor and incubated at 30°C for 3 h. Reaction samples were collected at different time points and reactions were stopped with the addition of acetonitrile. (B) and (C), SAH formation showed a linear range for 2 h under given reaction conditions with both VEEV nsP1 and CHIKV nsP1 when GIDP was used as a

methyl acceptor. Data points represent mean values and error bars are standard deviations from duplicate experiments. AU: arbitrary units.

FIG 5 Detection of m<sup>7</sup>GTP by pre-capillary CE method using PVA capillary. (A) Overlay of CEelectropherograms illustrating m<sup>7</sup>GTP formation by MTase activity of H37A mutant of VEEV nsP1 detected with PVA capillary. Black stars indicate the m<sup>7</sup>GTP peak. Electropherograms showing the separation of, (1) Authentic standards of GTP (with contaminating GDP) and m<sup>7</sup>GTP to determine standard migration time of each analyte, (2) MTase reaction products after methylation reaction was carried out for 60 min, (3) methylation reaction product with sinefungin in the reaction mixture under conditions and substrate concentrations mentioned in the methodology section. Separation of the analytes was performed using pressure injection with 50 mbar pressure for 10 s at -30 kV voltage using 75 mM MES buffer, pH 6.4 in a PVA capillary, 64.5 cm length (56 cm to the detector) and 50  $\mu$ m internal diameter. (B) Calibration curve of m<sup>7</sup>GTP detection using optimised CE method is linear over the concentration range 25-100  $\mu$ M. Linearity of m<sup>7</sup>GTP formation as a function of time as analysed by CE with UMP as the internal standard. Absorption was measured at 254 nm. IS: internal standard (UMP).

FIG 6 Dose-dependent inhibition obtained for VEEV nsP1 (A, B) and CHIKV nsP1 (C, D) by inhibitors: sinefungin (A,C) and ATA (B, D). MTase reaction was carried out by incubating the enzyme, SAM, and GIDP for 2 h with indicated concentrations of the inhibitors at reaction conditions discussed in the methodology section. The relative MTase activity is obtained by analysing the reaction mixture with CE and quantifying the corrected peak area of SAH formed during the reaction relative to the vehicle control.  $IC_{50}$  values of the inhibitors were calculated by curve-fitting in graph pad prism and are illustrated in Table 1. Data points represent mean values and error bars are standard deviation generated from duplicate experiments.

**FIG 7 Inhibitory effect of adenosine analogs on the MTase activity of nsP1.** (A) Inhibitors were tested at 50 μM concentration in the MTase reaction mixture of VEEV and CHIKV nsP1 and reaction was carried out as discussed in the methodology section. Relative MTase activity for VEEV nsP1 (black bars) and CHIKV nsP1 (grey bars) was calculated using vehicle control as 100%. (B) CHIKV nsP1 activity inhibition in the presence of 5-IT was determined by an ELISA assay in terms of the amount m<sup>7</sup>GMP-nsP1 adduct formation by anti-m<sup>7</sup>-GMP antibodies and the absorbance was measured at 450 nm. Data points represent mean values of relative activity and error bars are standard deviations from duplicate experiments.

**FIG 8 Anti-CHIKV activity of 5-IT.** (A) Monolayers of Vero cells were incubated with indicated concentrations of 5-IT for 24 h to evaluate cytotoxicity. MTT reagent was added and readings were taken at

570 nm. (B) Dose-response curve of 5-IT against CHIKV. Subconfluent Vero cell monolayer was infected with CHIKV (strain no. 119067) at MOI of 1 along with varying concentrations of 5-IT. 24 hpi culture supernatant was collected and subjected to viral titer determination using plaque assay. Percent reduction in viral titer was calculated with titer in vehicle-treated cells as 100%. (C) Immunofluorescence assay for the assessment of CHIKV inhibition by 5-IT. Cells were processed at 36 hpi, incubated sequentially with primary anti-alphaviral antibody and FITC-conjugated secondary antibody, and then counterstained with DAPI. This is a representative micrograph of multiple assessments. Scale bar, 200  $\mu$ m. (D) Chemical structure of 5-IT. (E) Reduction in intracellular viral RNA as assessed by qRT-PCR. Fold-reduction in viral RNA in treated cells relative to the control is plotted. Actin: endogenous control; CHIKV E1: target gene. (F) CHIKV viral titer (PFU/mI) at 24 hpi when 0.75  $\mu$ M 5-IT was added at indicated time points. Cells were infected with CHIKV at an MOI of 1 and viral titer was measured with standard plaques assay. Data points represent mean values and error bars are standard deviations from triplicate experiments. Significance of difference between viral RNA or PFU/ml in treated cells and vehicle control was measured by one-way ANOVA-test and Dunnett's post-test. \*\*\*, p< 0.001.

 TABLE 1: Validation parameters for the two CE methods: limit of detection, limit of quantitation, linearity of calibration curve, and reproducibility of migration time.

5	Analyte	SAH <sup>a</sup>	m7GTP⁵	
	Limit of detection (LOD)	0.5 μΜ	5 μΜ	
	Limit of quantification (LOQ)	1.5 μΜ	15 μΜ	
	Linearity of calibration curve; <i>R</i> <sup>2</sup>	0.9998	0.9865	
	Mean value of migration time (min) $\pm$	10.04 <u>+</u> 0.06	10.02 <u>+</u> 0.06	
	SD (n=12) <sup>c</sup>			
	RSD of migration time (%) <sup>d</sup>	0.61	0.54	
	Total separation time	11 min	12 min	

- <sup>a</sup> Using extended path-length fused-silica capillary
- <sup>b</sup> Using PVA coated capillary
- <sup>c</sup> SD, Standard deviation
- <sup>d</sup> RSD, Relative standard deviation

TABLE 2: Calculated IC<sub>50</sub> values of sinefungin and ATA for VEEV nsP1 and CHIKV nsP1.

Inhibitors	IC <sub>50</sub> (VEEV nsP1)	IC <sub>50</sub> (CHIKV nsP1)	IC <sub>50</sub> (VEEV nsP1) <sup>e</sup>
Sinefungin	$2.31\pm0.32~\mu M$	$2.94\pm0.74~\mu M$	$1.4\pm0.58~\mu M$
ATA	$21.86\pm2.56~\mu M$	$49.82\pm14.6~\mu M$	$56.9\pm1.59~\mu M$

<sup>e</sup> Values reported by Li et al., 2015

Α		1	10	20	30	40	50	60 70
	VEEV CHIKV Sindbis EEEV Aura RRV SFV ONNV	MEKVH MDSVY MEKPVVN MEKVH MEKPTVH MKVT . MAAKVH MDSVY	VDIEEDSPFL VDIDADSAFL VDVDPQSPFV VDLDADSPFV VDVDPQSPFV VDVEADSPFL VDIEADSPFI VDIEADSAFL	RALQRSFP KALQRAYP AQLQKSFP KSLQRCFP LQLQKSFP KALQKAFP KSLQKAFP KALQKAFP	QFEVEAKQVTD MFEVEPRQVTS QFEVVAQQATP HFEIEATQVTD QFEIVAQQVTP AFEVESQQVTP SFEVESLQVTP MFEVEPKQVTP	NDHANARAFSI NDHANARAFSI NDHANARAFSI NDHANARAFSI NDHANARAFSI NDHANARAFSI NDHANARAFSI	ILASKLIETEV ILAIKLIEQEI ILASKLIELEV ILASKLIEGEV ILASKLIEHEI ILATKLIEQEV ILATKLIEQET ILAIKLIEQEI	DPSD TILDIGSAPAR DPDS TILDIGSAPAR PTTATILDIGSAPAR DTDQVILDIGSAPAR PTSVTILDIGSAPAR PANITILDVGSAPAR DKDTLILDIGSAPSR DPDSTILDIGPAPAR
			вo	٥ö	100	110	120	130 140
	VEEV CHIKV Sindbis EEEV Aura RRV SFV ONNV	RMYSKHK RMMSDKK RMFSEHH HTHSKHK RMYSEHK RLMSDHS RMMSTHK RMMSDRK	YHCICPMRCA YHCVCPMRSA YHCVCPMRSP YHCICPMKSA YHCVCPMRSP YHCICPMKSA YHCVCPMRSA YHCVCPMRSA	EDPDRLYK EDPERLAN EDPDRMMK EDPDRLYR EDPDRLMN EDPERLAN EDPERLAN	YATKLKKNCKE YARKLASAAGK YANKLAEKANK YADKLRKSD YASRLADKAGE YARKLAKTAGE YARKLASAASGK YARKLASAAGK	I T DK E L D K KM H V L DR N I S G K I G I T N K N L H E K I H V T DK C I A S KA H I T N K R L H D K L H V L DK N V S G K I V L DR E I A G K I V T DK N I S G K I	KELAAVMSDPD       GDLQAVMAVPD       KDLRIVLDTPD       ADLLTVMSTPD       ADLLTVMSTPD       ADLLTVMSTPD       ADLLTVMSTPD       ADLLYVNSTPD       ADLQTVMATPD       IDLQTVMATPD       IDLQTVMATPD	LETETMCLHDDESCR TETPTFCLHTDVSCR AETPSLCFHNDVTCS AETPSLCFHNDVTCS AETPSLCHHTDSTCR AETGTICFHNDVICR LESPTFCLHTDETCR AESPTFCLHTDATCR
		15	0 16	0	170 1	80 19	20	0 210
	VEEV CHIKV Sindbis EEEV Aura RRV SFV ONNV	Y E G QVAV Q RA DVAI T RAEYSV Y HG SVAV T TAEVSV T RAEVAV T AAEVAV Q RG DVAI	YQDVYAVDGP YQDVYAVHAP MQDVY.INAP YQDVY.INAP YQDVY.INAP YQDVY.INAP YQDVY.XHAP YQDVYAVHAP YQDVYAVHAP	TSLYHQAN TSLYHQAI GTIYHQAM TSIYYQAL STIYHQAL TSLYHQAM TSLYHQAM TSLYHQAI	KGVRVAYWIGF KGVRVAYWVGF KGVRTIYWIGF KGVRTIYWIGF KGVRKIYWIGF KGVRTAYWIGF KGVRVAYWIGF	DTTPFMFKNL DTTPFMYNAM DTTQFMFSAM DTTPFMYKNM DTTQFMFSSM DTTPFMFEVV DTTPFMFDAL DTTPFMFNAM	AGAYPSYSTNW AGAYPSYSTNW AGSYPAYNTNW AGAYPTYNTNW AGSYPSYNTNW AGAYPTYSTNW AGAYPTYATNW AGAYPSYSTNW	ADETVLTARNIGLCS ADEQVLKAKNIGLCS ADEKVLEARNIGLCS ADESVLEARNIGLGS ADERVLEARNIGLCS ADEQVLQARNIGLCA ADEQVLQARNIGLCA
		220	230	24	o 250	260	270	280
	VEEV CHIKV Sindbis EEEV Aura RRV SFV ONNV	S D VMERS T D L TEGG T K L SEGR S D L HEKS T K L REGT T S L SEGH A S L TEGR T D L SEGR	RRGMSILRKK RGKLSIMRRK IGKLSIMRKK RGKLSIFRKK RGKISIMRKK LGKLSILRKK RGKLSIMRGK	Y LKPSNNV KLKPCDRV ELKPGSRV KLQPTNKV ALKPGTNV RLRPSDRX QLKPCDTV KLKPCDRV	LFSVGSTIYHE LFSVGSTLYPE YFSVGSTLYPE IFSVGSTIYTE YFSVGSTLYPE MFSVGSTLYIE MFSVGSTLYIE LFSVGSTLYPE	KRDLLRSWHL SRMLLKSWHL YRDSLQSWHL ERILLRSWHL SRRLKSWHL SRRLKSWHL SRKLLRSWHL SRKLLQSWHL	SVFHLRGKON SVFHLKGKLS SVFHLKGKQS NVFHLKGKQS SVFHLKGKQS SVFHLKGKNS SVFHLKGKQS SVFHLKGKLS	YTCRCETIVSCDGYV FTCRCDTVVSCEGYV YTCRCDTVVSCEGYV FTGRCNTIVSCEGYV FTCRCDTAVNCEGYV FTCRCDTIVSCEGYV FTCRCDTIVSCEGYV FTCRCDTIVSCEGYV











В



Α



Β

Α

С

Α



В



С



Mock-infected control

CHIKV-infected control 1 μM 5-IT

